NSCLC Patients With EGFR Activating Mutation Clinical Trial
Official title:
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
The current first line treatment of patients with EGFR activating mutation lung cancer is
EGFR TKI. Compared to platinum-based chemotherapy, EGFR-TKIs are superior in terms of
response rate and progression-free survival. However, an acquired resistance occurs almost
constantly. The second-line treatment includes platinum-based chemotherapy in the absence of
contraindication. This chemotherapy is then administered after discontinuing EGFR TKIs.
However, a rebound phenomenon of the disease was described in patients who discontinued EGFR
TKIs. Some clinical teams therefore recommend, as a precaution, in order to avoid any
withdrawal phenomenon, to never discontinue EGFR TKIs in patients developing an EGFR TKI
acquired resistance.
It seems therefore useful to conduct a study to better define the therapeutic strategy to
adopt in patients developing an acquired resistance after having received EGFR TKIs as first
line treatment.
n/a